BioCentury This Week de BioCentury

BioCentury 393 - Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.

For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

00:00

Episódios

24 ago. 2026

17 ago. 2026

10 ago. 2026

03 ago. 2026

27 jul. 2026

20 jul. 2026

15 jul. 2026

13 jul. 2026

06 jul. 2026

29 jun. 2026

22 jun. 2026

15 jun. 2026

10 jun. 2026

08 jun. 2026

01 jun. 2026

26 maio 2026

18 maio 2026

12 maio 2026

11 maio 2026

04 maio 2026

27 abr. 2026

22 abr. 2026

20 abr. 2026

13 abr. 2026

06 abr. 2026

01 abr. 2026

30 mar. 2026

23 mar. 2026

16 mar. 2026

13 mar. 2026

09 mar. 2026

02 mar. 2026

23 fev. 2026

17 fev. 2026

09 fev. 2026

02 fev. 2026

26 jan. 2026

22 jan. 2026

20 jan. 2026

15 jan. 2026

12 jan. 2026

05 jan. 2026

29 dez. 2025

15 dez. 2025

08 dez. 2025

01 dez. 2025

24 nov. 2025

21 nov. 2025

20 nov. 2025

17 nov. 2025

BioCentury This Week de BioCentury

Episódios

Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick

Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA

Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOs

Ep. 380 - AZ-BMS rumors, Replimune, psychedelics

Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard

Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data

Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson

Ep. 376 - M&A momentum: 3Q public markets preview

Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech

Ep. 374 - Parkinson's deep dive & FDA trial reforms

Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first

Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline

Ep. 371 - Moving faster at the academia-industry interface

Ep. 370 - Calmer waters for FDA; Servier, Lilly deals

Ep. 369 - ASCO advances, China innovation & U.S. science under threat

Ep. 368 - ASCO Preview, China Policy, ADC Linkers

Ep. 367 - FDA, obesity targets and the rise of DACs

Ep. 366 - Europe's need for speed: Bio€quity takeaways

Ep. 365 - Thin ice for Makary, redosing AAVs

Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies

Ep. 363 - New targets at AACR, biopharma deals, Kurma fund

Ep. 362 - AACR: Data and de-risking

Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers

Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds

Ep. 359 - 2Q markets preview, tariffs and biotech takeouts

Ep. 358 - Europe's biotech challenge

Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision

Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN

Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline

Ep. 354 - East-West Summit Takeaways

Ep. 353 - Prasad Departure and Future of Fibrosis Therapies

Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight

Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint

Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA

Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch

Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules

Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos

Ep. 346 - 2026 Public Markets Preview

Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN

Ep. 344 - JPM Momentum and Asia’s Hotbeds of Innovation

Ep. 343 - JPM Deals, Policy Outlook, Approval Trends

Ep. 342 - 2026 Biotech Kickoff

Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI

Ep. 340 - Obesity Data, Kymera & FDA Survey Results

Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult

Ep. 338 - Semaglutide’s Alzheimer’s Miss. Plus: Vaccine Policy, Cell, Gene Therapy Funding

Ep. 337 - FDA’s Moving Goalposts & China’s Innovation Arc

Ep. 336 - Cautious Optimism and M&A Momentum

Ep. 335 - Neurology's Coming Inflection Point

Ep. 334 - Pazdur’s New FDA Role, SITC & China RNAi